Game-Changers in Diabetes Care? The Rise of Icodec and Efsitora

Introduction: A New Era in Diabetes Care - The Rise of Once-Weekly Insulin Therapy For decades, people living with diabetes have had to rely on daily insulin injections to manage their blood glucose levels — a routine that often comes with physical, emotional, and practical challenges. But the landscape of diabetes care is rapidly evolving. … Continue reading Game-Changers in Diabetes Care? The Rise of Icodec and Efsitora

Weekly DPP-4 Inhibitors: ‘Trelagliptin & Omarigliptin’, Overlooked or Underrated? A Potential Game Changer for Diabetes Care in Developing Countries

Trelagliptin and Omarigliptin represent a significant advancement in diabetes management as once-weekly DPP-4 inhibitors. They promise improved patient compliance, simplified regimens, and enhanced glycemic control. While offering cost-effective and practical solutions for diabetes care, especially in resource-limited settings, challenges like long-term safety data must be addressed for broader adoption.